Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, when he expects the final results of the National Institute for Health Research's ProtecT trials for prostate cancer testing to be published; and if he will make a statement.

The ProtecT randomised controlled trial is evaluating the effectiveness, cost-effectiveness and acceptability of active monitoring, radical 3D conformal radiotherapy and radical prostatectomy in men with clinically localised prostate cancer, identified through population-based PSA (Prostate Specific Antigen) testing.

There have already been over 100 published outputs from ProtecT and these are listed on the National Institute for Health Research (NIHR) website:

www.nets.nihr.ac.uk/projects/hta/962099

The researchers plan to publish the primary and most secondary analyses during 2016 at major relevant conferences and in peer-reviewed journals. The primary outcome to be evaluated is definite or probable prostate cancer specific mortality at a median of 10 years following randomisation. A monograph covering these findings is expected to be published in the NIHR Journals Library in July 2017. Findings from longer term follow-up will be published at a later stage.